MYLAXEN Drug Patent Profile
When do Mylaxen patents expire, and when can generic versions of Mylaxen launch?
Mylaxen is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.
The generic ingredient in MYLAXEN is hexafluorenium bromide. There is one drug master file entry for this compound. Additional details are available on the hexafluorenium bromide profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MYLAXEN?
- What are the global sales for MYLAXEN?
- What is Average Wholesale Price for MYLAXEN?
Summary for MYLAXEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 38 |
| Patent Applications: | 719 |
| DailyMed Link: | MYLAXEN at DailyMed |
US Patents and Regulatory Information for MYLAXEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medpointe Pharm Hlc | MYLAXEN | hexafluorenium bromide | INJECTABLE;INJECTION | 009789-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
